Simultaneous quantitation of abiraterone, enzalutamide, N‐desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS

[1]  D. Somford,et al.  Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration–Resistant Prostate Cancer , 2018, Therapeutic drug monitoring.

[2]  C. Bakkenist,et al.  LC–MS/MS assay for the quantitation of the ATR kinase inhibitor VX‐970 in human plasma , 2017, Journal of pharmaceutical and biomedical analysis.

[3]  A. Gao,et al.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. , 2015, American journal of clinical and experimental urology.

[4]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[5]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[6]  A. Paci,et al.  Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. , 2014, European journal of cancer.

[7]  N. Kang,et al.  Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study. , 2014, Biomedical chromatography : BMC.

[8]  Z. Culig.  Targeting the androgen receptor in prostate cancer , 2014, Expert opinion on pharmacotherapy.

[9]  P. Troncoso,et al.  Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). , 2014 .

[10]  Yoshiaki Ohtsu,et al.  Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS. , 2014, Bioanalysis.

[11]  H. Tsukamoto,et al.  A validated quantitative liquid chromatography-tandem quadrupole mass spectrometry method for monitoring isotopologues to evaluate global modified cytosine ratios in genomic DNA. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[13]  S. Rajagopal,et al.  Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. , 2012, Biomedical chromatography : BMC.

[14]  S. Keam,et al.  Bicalutamide 150mg , 2012, Drugs.

[15]  P. Dasgupta,et al.  Expanding the linear dynamic range for multiple reaction monitoring in quantitative liquid chromatography-tandem mass spectrometry utilizing natural isotopologue transitions. , 2011, Talanta.

[16]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[17]  G. Sonpavde.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[18]  S. Glina,et al.  Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. , 2010, The journal of sexual medicine.

[19]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  K. Yu,et al.  Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. , 2009, Clinical therapeutics.

[21]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  S. Keam,et al.  Bicalutamide 150 mg A Review of its Use in the Treatment of Locally Advanced Prostate Cancer , 2006 .

[24]  F. Boccardo,et al.  Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer , 2005, Cancer Chemotherapy and Pharmacology.

[25]  Jos H. Beijnen,et al.  BIOANALYTICAL LIQUID CHROMATOGRAPHIC METHOD VALIDATION. A REVIEW OF CURRENT PRACTICES AND PROCEDURES , 2000 .

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.